BioLineRx (NASDAQ:BLRX) Shares Cross Above 200-Day Moving Average – Here’s What Happened

BioLineRx Ltd. (NASDAQ:BLRX) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.87 and traded as high as $3.07. BioLineRx shares last traded at $2.98, with a volume of 7,371 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

BioLineRx Price Performance

The company has a 50 day moving average of $3.16 and a 200 day moving average of $2.87. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.43 and a current ratio of 1.58. The stock has a market capitalization of $13.02 million, a price-to-earnings ratio of -1.55 and a beta of 1.55.

BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.68. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The company had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.34 million.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.